Business
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited resultsProvides full ye
About this update from Ani Pharmaceuticals, Inc.
[{"type":"image","alt":"ANI Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"ANI Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":270,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/affa8ae63629bff3d190d327bdae162e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ropAbm4enKilJXBFvyz.RQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/affa8ae63629bff3d190d327bdae162e","width":270,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively","length":241,"tagName":"p"}]},{"val":[{"type":"text","content":"Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results","length":243,"tagName":"p"}]},{"val":[{"type":"text","content":"Provides full year 2026 financial guidance, which includes:","length":59,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total net revenues of $1,055 million to $1,115 million","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Cortrophin Gel net revenues of $540 million to $575 million","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted non-GAAP EBITDA of $275 million to $290 million","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Rare Disease business to represent approximately 60% of total net revenues","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false}]},{"val":[{"type":"text","content":"Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026","length":172,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":958,"olType":false},{"type":"text","content":"PRINCETON, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced preliminary select financial results...